Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1053

—

85698ae3-c971-5775-ae8e-9914de6b1b46

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.483
  • MYC_TARGETS_V1+0.476
  • OXIDATIVE_PHOSPHORYLATION+0.400
  • PEROXISOME+0.372
  • DNA_REPAIR+0.324
  • HEME_METABOLISM+0.293
  • MYC_TARGETS_V2+0.290
  • MITOTIC_SPINDLE+0.270
  • UNFOLDED_PROTEIN_RESPONSE+0.249
  • MTORC1_SIGNALING+0.239

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.494
  • INTERFERON_ALPHA_RESPONSE-0.372
  • INTERFERON_GAMMA_RESPONSE-0.325
  • TNFA_SIGNALING_VIA_NFKB-0.320
  • PANCREAS_BETA_CELLS-0.312
  • HYPOXIA-0.290
  • IL6_JAK_STAT3_SIGNALING-0.289
  • MYOGENESIS-0.288
  • KRAS_SIGNALING_UP-0.256
  • ALLOGRAFT_REJECTION-0.243

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SJEPD030060_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.881
2R122
bladder-landscape@3
——0.869
3MNG1038
mng-umap@100
——0.867
4E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18
brain-umap@2
——0.863
5SJEPD030833_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.860
6MNG434
mng-umap@100
——0.860
7MNG458
mng-umap@100
——0.852
8MNG1022
mng-umap@100
——0.850
9MNG1176
mng-umap@100
——0.847
10TCGA-46-3768-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.839

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.483Remibrutinib— uncovered
MYC_TARGETS_V10.476Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
PEROXISOME0.372Idelalisib— uncovered
DNA_REPAIR0.324Idelalisib— uncovered
HEME_METABOLISM0.293Temsirolimus— uncovered
MYC_TARGETS_V20.290Idelalisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.249Idelalisib— uncovered
MTORC1_SIGNALING0.239Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.225Inavolisib— uncovered
NOTCH_SIGNALING0.199Inavolisib— uncovered
ANDROGEN_RESPONSE0.198Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.194Remibrutinib— uncovered
ADIPOGENESIS0.182Inavolisib— uncovered
G2M_CHECKPOINT0.168Inavolisib— uncovered
FATTY_ACID_METABOLISM0.163Inavolisib— uncovered
BILE_ACID_METABOLISM0.146Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.145Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.126Inavolisib— uncovered